Success Metrics

Clinical Success Rate
74.1%

Based on 43 completed trials

Completion Rate
74%(43/58)
Active Trials
26(20%)
Results Posted
26%(11 trials)
Terminated
15(12%)

Phase Distribution

Ph phase_1
16
12%
Ph phase_2
20
16%
Ph not_applicable
41
32%
Ph phase_3
2
2%
Ph early_phase_1
9
7%
Ph phase_4
3
2%

Phase Distribution

25

Early Stage

20

Mid Stage

5

Late Stage

Phase Distribution91 total trials
Early Phase 1First-in-human
9(9.9%)
Phase 1Safety & dosage
16(17.6%)
Phase 2Efficacy & side effects
20(22.0%)
Phase 3Large-scale testing
2(2.2%)
Phase 4Post-market surveillance
3(3.3%)
N/ANon-phased studies
41(45.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.7%

43 of 60 finished

Non-Completion Rate

28.3%

17 ended early

Currently Active

26

trials recruiting

Total Trials

129

all time

Status Distribution
Active(38)
Completed(43)
Terminated(17)
Other(31)

Detailed Status

Completed43
unknown31
Recruiting17
Terminated15
Not yet recruiting12
Active, not recruiting9

Development Timeline

Analytics

Development Status

Total Trials
129
Active
26
Success Rate
74.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 19 (9.9%)
Phase 116 (17.6%)
Phase 220 (22.0%)
Phase 32 (2.2%)
Phase 43 (3.3%)
N/A41 (45.1%)

Trials by Status

not_yet_recruiting129%
recruiting1713%
terminated1512%
active_not_recruiting97%
unknown3124%
withdrawn22%
completed4333%

Recent Activity

Clinical Trials (129)

Showing 20 of 129 trialsScroll for more
NCT07285993Phase 2

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

Not Yet Recruiting
NCT07325253Phase 2

A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Chronic Graft Versus Host Disease Manifestations

Recruiting
NCT06941480Phase 1

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

Not Yet Recruiting
NCT07523997

Imaging of Endometriosis With Total-body PET-CT (PET-Endo)

Not Yet Recruiting
NCT05513027Not Applicable

Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection

Terminated
NCT04668872

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Recruiting
NCT04018053Early Phase 1

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Active Not Recruiting
NCT03851237Phase 1

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

Completed
NCT03195777Not Applicable

Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT

Completed
NCT07243873

Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study

Recruiting
NCT06479187Phase 4

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Active Not Recruiting
NCT06062745Phase 1

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Recruiting
NCT02633111

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Active Not Recruiting
NCT04519580

Improved Diagnostics and Monitoring of Polymyalgia Rheumatica

Active Not Recruiting
NCT06047561

The Scottish Aortic Stenosis LongiTudinal Imaging and biomarkeR (SALTIRE) Programme

Recruiting
NCT04609592Phase 1

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Recruiting
NCT02608216Phase 1

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

Active Not Recruiting
NCT07127627

Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

Not Yet Recruiting
NCT03314636Phase 2

Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

Active Not Recruiting
NCT01879657Not Applicable

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
129